Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal ‐P)
Diabetes Obesity and Metabolism2013Vol. 15(11), pp. 1000–1007
Citations Over TimeTop 1% of 2013 papers
M. Pinget, Ronald Goldenberg, Elisabeth Niemoeller, Isabel Muehlen-Bartmer, Hailing Guo, Ronnie Aronson
Abstract
Lixisenatide once daily significantly improved glycaemic control with a low risk of hypoglycaemia, and was well tolerated over 24 weeks and during the long-term, double-blind extension period in patients with T2DM insufficiently controlled on pioglitazone ± metformin.
Related Papers
- → Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas(2011)31 cited
- → Pioglitazone/Metformin(2006)20 cited
- → Metformin for Prevention of Type 2 Diabetes(2004)11 cited
- → Clinical efficacy of pioglitazone combined with metformin in type 2 diabetes patients(2010)
- → Evaluation of the metformin initiation rate in veterans with newly identified type 2 diabetes(2021)